

Resource Summary Report

Generated by [dkNET](#) on Sep 16, 2026

PE anti-human CD14

RRID:AB_830679

Type: Antibody

Proper Citation

BioLegend Cat# 325606, RRID:AB_830679

Antibody Information

URL: http://antibodyregistry.org/AB_830679

Proper Citation: BioLegend Cat# 325606, RRID:AB_830679

Target Antigen: CD14

Host Organism: mouse

Clonality: monoclonal

Comments: Applications: FC

Antibody Name: PE anti-human CD14

Description: This monoclonal targets CD14

Target Organism: human

Clone ID: Clone HCD14

Antibody ID: AB_830679

Vendor: BioLegend

Catalog Number: 325606

Alternative Catalog Numbers: 325605

Record Creation Time: 20231110T043157+0000

Record Last Update: 20260829T204426+0000

Ratings and Alerts

No rating or validation information has been found for PE anti-human CD14.

No alerts have been found for PE anti-human CD14.

Data and Source Information

Source: [Antibody Registry](#)

Usage and Citation Metrics

We found 5 mentions in open access literature.

Listed below are recent publications. The full list is available at [dkNET](#) .

Li YR, et al. (2026) Spatiotemporal profiling reveals distinct dynamics and checkpoint regulations of CAR-T and CAR-NKT cells against solid tumors. Signal transduction and targeted therapy, 11(1).

Lu M, et al. (2026) Homeostatic maturation programs drive human cDC2s into a tolerogenic state. Immunity, 59(5), 1201.

Wu X, et al. (2023) Multiomic landscape of immune pathogenesis in Kimura's disease. iScience, 26(4), 106559.

Woan KV, et al. (2021) Harnessing features of adaptive NK cells to generate iPSC-derived NK cells for enhanced immunotherapy. Cell stem cell, 28(12), 2062.

Morrissey SM, et al. (2021) Tumor-derived exosomes drive immunosuppressive macrophages in a pre-metastatic niche through glycolytic dominant metabolic reprogramming. Cell metabolism, 33(10), 2040.